Last reviewed · How we verify
Lidocaine medicated plaster 5%
At a glance
| Generic name | Lidocaine medicated plaster 5% |
|---|---|
| Also known as | Versatis |
| Sponsor | Scilex Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study With Lidocaine 5% Medicated Plaster in Patients Suffering From Postherpetic Neuralgia (PHASE3)
- A Study With Lido-Patch and Placebo Plaster in Patients Suffering From Postherpetic Neuralgia (PHN) (PHASE3)
- 5% Lidocaine-medicated Plaster for the Treatment of Trigeminal Neuralgia (PHASE4)
- Localized Neuropathic Pain: Topical Treatment Versus Systemic Treatment (PHASE4)
- Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Lidocaine Patch 5% and Lidocaine Medicated Plaster 5% in Healthy, Adult, Human Subjects (PHASE1)
- Lidocaine 5% Medicated Plaster in Chronic Neuropathic Postoperative Pain (PHASE2)
- Efficacy and Safety of Topical Versus Systemic Treatment in Postherpetic Neuralgia and Diabetic Polyneuropathic Pain (PHASE3)
- Impact of 5% Lidocaine Medicated Plaster on Allodynic Symptoms of Localized Neuropathic Pain After Knee Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lidocaine medicated plaster 5% CI brief — competitive landscape report
- Lidocaine medicated plaster 5% updates RSS · CI watch RSS
- Scilex Pharmaceuticals, Inc. portfolio CI